Neurofibromatosis, type 2 (acoustic neurofibromatosis) MedDRA version: 14.0 Level: LLT Classification code 10029271 Term: Neurofibromatosis, type 2 (acoustic neurofibromatosis) System Organ Class: 10010331 - Congenital, familial and genetic disorders
Conditions
Interventions
Trade Name: Nexavar
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: sorafenib (as tosylate)
Other descriptive name: Nexavar
Sponsors
Plymouth Hospital NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (a)written informed consent (b)diagnosis of NF2 (c)over 18 years in age (d)presence of more at least two cutaneous schwannomas >1cm3 in area and accessible for biopsy (e)WHO/ECOG Performance Status 0 or 1 (f)adequate bone marrow function within 28 days prior to the baseline visit o WBC > 3.4x109/l o platelets > 99x109/l (g)adequate renal function within 28 days prior to the baseline visit o creatinine =65 years) yes F.1.3.1 Number of subjects for this age range 0
Exclusion criteria
Exclusion criteria: (a)hypersensitivity to sorafenib or any of its excipients (b)cardiac arrhythmias requiring anti-arrhythmics (beta-blockers and digoxin are allowed) (c)symptomatic coronary artery disease or ischemia (d)myocardial infarction (MI) within the last six months; congestive cardiac failure > NYHA Class II (e)active clinically serious bacterial or fungal infections (f)known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C (g)pregnant or breast-feeding (h)patients with uncontrolled hypertension (i)serious uncontrolled concomitant medical or psychiatric illness (j)concomitant medications o which have adverse interactions with sorafenib: rifampicin, ritonavir, ketoconazole, itraconazole and St John’s Wort o treatment with strong CYP3A4 inhibitors (e.g., erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil) which has not been discontinued or switched to a different medication at least 2 weeks prior to starting the study drug. o Treatment with strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbitol, St John’s Wort), which has not been discontinued or switched to a different medication at least 2 weeks prior to starting the study drug. (k)Grade 3 or higher impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome) (l)history of acute pancreatitis within one year of study entry or medical history of chronic pancreatitis (m)history of another primary malignancy that is currently clinically significant or currently requires active intervention. (n)any other clinically significant medical or surgical condition which, according to the CI/PI’s discretion, should preclude participation (o)history of significant congenital or acquired bleeding disorder • patients taking warfarin or cytotoxic drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objectives of the study are: To measure steady-state plasma concentrations and intra-tumoural concentrations of sorafenib in cutaneous schwannomas after 11 days of oral dosing with sorafenib To investigate indices of molecular activity of sorafenib in tumour and blood, before and after treatment with sorafenib.;Secondary Objective: The secondary objectives of the study are: To assess whether target inhibition with oral sorafenib in plasma in NF2 patients with CS can act as a biomarker To analyze if tumour pain occurs after treatment with oral sorafenib in NF2 To identify early drug induced changes in the MRI scan (Manchester only);Primary end point(s): Target inhibition by sorafenib in cutaneous schwannoma biopsies | — |
Countries
United Kingdom
Outcome results
None listed